GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2808.4

(-0.26%)

Operating Expenses Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual operating expenses in 2023 was 4.35 Billion INR , down -61.93% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly operating expenses in 2024 Q2 was 3.21 Billion INR , up 11.85% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a annual operating expenses of 11.44 Billion INR in annual operating expenses 2022, up 1.33% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a annual operating expenses of 11.29 Billion INR in annual operating expenses 2021, up 9.41% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating expenses of 1.37 Billion INR for 2024 Q1, up 3.76% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating expenses of 1.32 Billion INR for 2023 Q4, down -53.88% from previous quarter.

Annual Operating Expenses Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Operating Expenses of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Operating Expenses	Operating Expenses Growth
2023	4.35 Billion INR	-61.93%
2022	11.44 Billion INR	1.33%
2021	11.29 Billion INR	9.41%
2020	10.32 Billion INR	-23.39%
2019	13.47 Billion INR	19.57%
2018	11.27 Billion INR	5.61%
2017	10.67 Billion INR	3.19%
2016	10.34 Billion INR	8.21%
2015	9.55 Billion INR	-1.14%
2014	9.66 Billion INR	19.94%
2013	8.05 Billion INR	15.73%
2012	6.96 Billion INR	7.55%
2011	6.47 Billion INR	31.79%
2010	4.91 Billion INR	10.55%
2009	4.44 Billion INR	32.03%
2008	3.36 Billion INR	-3.4%
2007	3.48 Billion INR	-9.29%
2006	3.84 Billion INR	-1.79%
2005	3.91 Billion INR	3.41%
2004	3.78 Billion INR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	3.21 Billion INR	11.85%
2024 Q1	1.37 Billion INR	3.76%
2023 Q4	1.32 Billion INR	-53.88%
2023 Q2	3.31 Billion INR	-2.03%
2023 Q3	2.87 Billion INR	-13.2%
2023 FY	4.35 Billion INR	-61.93%
2023 Q1	3.38 Billion INR	63.81%
2022 FY	11.44 Billion INR	1.33%
2022 Q1	3.25 Billion INR	62.72%
2022 Q2	3.11 Billion INR	-4.28%
2022 Q3	3.01 Billion INR	-2.98%
2022 Q4	2.06 Billion INR	-31.66%
2021 Q3	3.15 Billion INR	2.93%
2021 Q2	3.06 Billion INR	-0.09%
2021 Q4	1.99 Billion INR	-36.74%
2021 FY	11.29 Billion INR	9.41%
2021 Q1	3.07 Billion INR	48.19%
2020 Q3	2.79 Billion INR	-14.92%
2020 Q2	3.28 Billion INR	10.03%
2020 Q1	2.98 Billion INR	-14.81%
2020 FY	10.32 Billion INR	-23.39%
2020 Q4	2.07 Billion INR	-25.96%
2019 Q4	3.5 Billion INR	1.79%
2019 FY	13.47 Billion INR	19.57%
2019 Q3	3.44 Billion INR	1.16%
2019 Q2	3.4 Billion INR	9.61%
2019 Q1	3.1 Billion INR	51.28%
2018 Q3	3.17 Billion INR	1.27%
2018 FY	11.27 Billion INR	5.61%
2018 Q4	2.05 Billion INR	-35.3%
2018 Q2	3.13 Billion INR	8.11%
2018 Q1	2.9 Billion INR	0.0%
2017 Q1	2.99 Billion INR	0.0%
2017 FY	10.67 Billion INR	3.19%
2016 FY	10.34 Billion INR	8.21%
2015 FY	9.55 Billion INR	-1.14%
2014 FY	9.66 Billion INR	19.94%
2013 FY	8.05 Billion INR	15.73%
2012 FY	6.96 Billion INR	7.55%
2011 FY	6.47 Billion INR	31.79%
2010 FY	4.91 Billion INR	10.55%
2009 FY	4.44 Billion INR	32.03%
2008 FY	3.36 Billion INR	-3.4%
2007 FY	3.48 Billion INR	-9.29%
2006 FY	3.84 Billion INR	-1.79%
2005 FY	3.91 Billion INR	3.41%
2004 FY	3.78 Billion INR	0.0%

Peer Operating Expenses Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Operating Expenses	Operating Expenses Difference
Abbott India Limited	5.98 Billion INR	27.21%
Cipla Limited	59.21 Billion INR	92.642%
Gland Pharma Limited	3.86 Billion INR	-12.838%
Kopran Limited	859.54 Million INR	-406.935%
Marksans Pharma Limited	3.28 Billion INR	-32.465%
NGL Fine-Chem Limited	816.16 Million INR	-433.882%
Pfizer Limited	4.33 Billion INR	-0.465%
Sanofi India Limited	3.69 Billion INR	-17.99%
SMS Pharmaceuticals Limited	370.89 Million INR	-1074.828%